TCRX Q1 2024 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$566,000-91.7% YoY

Gross Profit

$566,000100.0% margin

Operating Income

-$31M-5542.9% margin

Net Income

-$30M-5325.4% margin

EPS (Diluted)

$-0.32

QoQ Revenue Growth

-92.2%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$30M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$241M

Total Liabilities

$118M

Stockholders' Equity

$123M

Cash & Equivalents

$141M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$566,000	$7M	-91.7%
Gross Profit	$566,000	$7M	-91.7%
Operating Income	-$31M	-$23M	-37.9%
Net Income	-$30M	-$23M	-33.6%